Intestinal Microbiome Associated with Efficacy of Atezolizumab and Bevacizumab Therapy for Hepatocellular Carcinoma

The combination of atezolizumab and bevacizumab has become the first-line treatment for patients with unresectable hepatocellular carcinoma (HCC). However, no studies have reported on specific intestinal microbiota associated with the efficacy of atezolizumab and bevacizumab. In this study, we analy...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2024-05, Vol.16 (9), p.1675
Main Authors: Inukai, Yosuke, Yamamoto, Kenta, Honda, Takashi, Yokoyama, Shinya, Ito, Takanori, Imai, Norihiro, Ishizu, Yoji, Nakamura, Masanao, Ishigami, Masatoshi, Kawashima, Hiroki
Format: Article
Language:English
Subjects:
Alcohol
Antibiotics
Bacteria
Bacteroides
Bevacizumab
Combination therapy
Development and progression
Diabetes
Digestive system
Drug therapy
Feces
Gastrointestinal tract
Health aspects
Hepatitis B
Hepatitis C
Hepatocellular carcinoma
Hepatoma
Intestinal microflora
Intestine
Liver cancer
Microbiomes
Microbiota
Microbiota (Symbiotic organisms)
Parabacteroides
Patients
Prognosis
Rifaximin
Survival analysis
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The combination of atezolizumab and bevacizumab has become the first-line treatment for patients with unresectable hepatocellular carcinoma (HCC). However, no studies have reported on specific intestinal microbiota associated with the efficacy of atezolizumab and bevacizumab. In this study, we analyzed fecal samples collected before treatment to investigate the relationship between the intestinal microbiome and the efficacy of atezolizumab and bevacizumab. A total of 37 patients with advanced HCC who were treated with atezolizumab and bevacizumab were enrolled. Fecal samples were collected from the patients, and they were divided into responder ( = 28) and non-responder ( = 9) groups. We compared the intestinal microbiota of the two groups and analyzed the intestinal bacteria associated with prognosis using QIIME2. The alpha and beta diversities were not significantly different between both groups, and the proportion of microbiota was similar. The relative abundance of and was higher in the responder group than in the non-responder group. When the prognosis was analyzed by the presence or absence of those bacteria, patients without both had a significantly poorer prognosis. Differences in intestinal microbiome are involved in the therapeutic effect of atezolizumab and bevacizumab.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers16091675